Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 109

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 109
---
 financial, and operational benefits in approving the Merger, significant risks remain. The success of the Merger will depend on careful execution, effective integration strategies, and proactive risk management. See “ Risk Factors — Risks Related to the Merger” in this proxy statement/prospectus. The Kadimastem Board considered various factors that supported its decision to approve the Merger Agreement, including: Strategic Synergies •Complementary Strengths: The combined expertise and product portfolio enhance the combined company’s ability to deliver comprehensive solutions. •Market Expansion: Operating in new geographies or market segments increases reach and diversification. •Strengthened Competitive Position: A larger entity is better equipped to navigate industry competition. Financial Benefits •Operational Efficiencies: Eliminating redundancies reduces costs and potentially increases profitability. •Growth Potential: Access to new revenue opportunities and markets strengthens the financial outlook. •Resource Consolidation: The Merger creates a more robust financial foundation. Advantages to Kadimastem Officers and Directors •Increased Value for Shares Held by Insiders: Increased value for shares held by insiders due to Nasdaq liquidity and valuation advantages. •Increased Credibility: Advantages of being Nasdaq -listedcompany and potential created from enhanced status. Innovation and Collaboration •Accelerated R&D: Sharing research and resources accelerates innovation in key areas, including diabetes. •Improved Product Development: Unified efforts enhance time -to-marketefficiency. Operational Strengths •Enhanced Infrastructure: Consolidation leads to improved technological and operational frameworks. •Stronger Workforce: Combining teams increases capacity and innovation potential. Competitive Landscape •Industry Leadership: Kadimastem believes that Merger positions the combined company as a leader in its field of regenerative medicine. By harnessing the synergy of cellular therapies and novel therapeutic molecules the Merger brings innovative approaches to enhance therapeutic outcomes. •Defensive Strategy: Merging reduces vulnerabilities to external threats and competition. 12 Shareholder Value •Enhanced Returns:Improved operational efficiency and revenue generation are expected to drive shareholder value. •Long -TermGrowth:A unified strategy fosters sustainable growth opportunities. •Risk Mitigation:Diversification of products, regions, and customer bases reduces potential risks. Vision and Cultural Alignment •Unified Mission:A shared vision enhances focus on long -termgoals. •Integration Potential: Strong cultural alignment is expected to ensure successful integration post -Merger. The Kadimastem Board also considered the valuation reports and the fairness opinions prepared by Moore, an independent financial advisor retained by Kadimastem